Treatment with new oral anticoagulants in primary care practices

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00006862

Enrollment

200

Registered

2015-03-06

Start date

2015-02-05

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

I48

Interventions

Group 1: non-interventional retrospective observational study. Documentation of medical records of GP patients who have been prescribed new oral anticoagulants (Dabigatran (Pradaxa®), Rivaroxaban (Xa

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: GP patients who have been prescribed in the past two years one of the drugs of Pradaxa, Xarelto and Eliquis

Exclusion criteria

Exclusion criteria: Duration of warfarin-taking before changing to the new oral anticoagulants <6 months

Design outcomes

Primary

Measure	Time frame
TTR at the time of a change from VKA to NOAK (calculation with a formula including INR values)	—

Secondary

Measure	Time frame
Reason for the change of VKA to NOAK (information from the electronic patient data or personal conversation with the concerned doctor)	—

Countries

Germany

Contacts

Public ContactBettina Weber

Institut für Hausarztmedizin, Universitätsklinikum Bonn

Bettina.Weber@ukb.uni-bonn.de0228/28711156

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026